Biochemical mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to stavudine

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 7, 2001, Pages 2144-2146

  Lennerstrand, J ^a   Stammers, D K ^a   Larder, B A ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; RNA DIRECTED DNA POLYMERASE; STAVUDINE;

ARTICLE; CODON; CYTOLYSIS; DRUG BINDING; GENE INSERTION; HUMAN IMMUNODEFICIENCY VIRUS 1; MUTATION; NONHUMAN; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; VIRUS RESISTANCE;

ADENOSINE TRIPHOSPHATE; AMINO ACID SUBSTITUTION; BINDING SITES; DRUG RESISTANCE, MICROBIAL; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE;

EID: 0034963036     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.7.2144-2146.2001     Document Type: Article

References (26)

1. Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′-deoxythymidine (AZT): Increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase
2. A sensitive assay for the quantification of reverse transcriptase activity based on the use of carrier-bound template and non-radioactive-product detection, with special reference to human immunodeficiency virus isolation
3. Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay
4. Signifcance of amino acid variation at human immunodefieiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility
5. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs
6. Stavudine: An update of its use in the treatment of HIV infection
7. Recombinant virus assay: A rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates
8. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine
9. Single-step kinetics of HIV-1 reverse transcriptase mutants responsible for virus resistance to nucleoside inhibitors zidovudine and 3-TC
10. Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2′,3′-didehydro-2′,3′-dideoxythymidine in cell culture
11. Biochemical studies on the reverse transcriptase and RNase H activities from human immunodeficiency virus strains resistant to 3′-azido-3′-deoxythymidine
12. Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing
13. A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance
14. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT)
15. Related functional domains in virus DNA polymerases
16. Correlation between viral resistance to zidovudine and resistance at the reverse transcriptase level for a panel of human immunodeficiency virus type 1 mutants
17. Application of a chain termination assay for characterisation of reverse transcriptase from AZT-resistant HIV isolates
18. Stavudine resistance: An update on susceptibility following prolonged therapy
19. Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy
20. A mechanism of AZT resistance: An increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase
21. Differential removal of thymidine nucleotide analogues from blocked DNA chains by human immunodeficiency virus reverse transcriptase in the presence of physiological concentrations of 2′-deoxynueleoside triphosphates
22. A non-radioactive microtitre plate reverse transcriptase (RT) assay, based on immobilized template, for screening of RT activity inhibitors and evaluation of their mode of action
23. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides
24. Crystals of HIV-1 reverse transcriptase diffracting to 2.2 A resolution
25. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase
26. Anti-human immunodeficiency virus drug combination strategies